The Role of ERK1/2 in Breast Cancer Prognosis
Author Information
Author(s): Milde-Langosch K, Bamberger A-M, Rieck G, Grund D, Hemminger G, Müller V, Löning T
Primary Institution: University Clinics Hamburg-Eppendorf (UKE)
Hypothesis
High expression of activated ERK1/2 is associated with better prognosis in breast cancer.
Conclusion
High levels of phosphorylated ERK1 expression are linked to longer recurrence-free and overall survival in breast cancer patients.
Supporting Evidence
- High p-ERK1 expression correlated with low frequency of recurrences.
- Strong p-ERK staining was associated with early stages of cancer.
- Negative nodal status was linked to high p-ERK expression.
Takeaway
This study found that a protein called p-ERK1 helps predict how well breast cancer patients will do, with higher levels meaning better outcomes.
Methodology
The study analyzed 148 breast cancer samples using immunoblotting and immunohistochemistry to assess ERK1/2 expression and correlated findings with clinical data.
Potential Biases
Potential bias due to the retrospective nature and selection of samples.
Limitations
The study is retrospective and may not account for all variables affecting patient outcomes.
Participant Demographics
147 female patients and 1 male patient, mean age 57 years, range 25–90 years.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website